Radius announces first patient randomized in the rad011 pivotal trial for prader-willi syndrome

Boston, july 07, 2022 (globe newswire) -- radius health, inc. ("radius" or the "company") (nasdaq: rdus) today announced the first patient has been randomized in the phase 2/3 pivotal study, scout-015, to evaluate rad011, a synthetic cannabidiol oral solution, for the treatment of hyperphagia and related neuro-behavioral symptoms in prader-willi syndrome (pws), a rare neuro-endocrine orphan disease which effects between approximately 20,000 and 30,000 patients in the us.
RDUS Ratings Summary
RDUS Quant Ranking